P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.

P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.

Bibliographic Details
Main Authors:	N. Asherie, S. Kfir-Erenfeld, B. Avni, S. Grisariu, M. Assayag, T. Sharon, E. Lebel, C. J. Cohen, M. E. Gatt, P. Stepensky
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846424.39371.7a

Similar Items

Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
by: Vladimir Vainstein, et al.
Published: (2023-07-01)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
by: Endeshaw Chekol Abebe, et al.
Published: (2022-09-01)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
by: Heng Mei, et al.
Published: (2021-10-01)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: C. Li, et al.
Published: (2022-06-01)

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
by: Lingzhi Yan, et al.
Published: (2021-01-01)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
by: Kai Rejeski, et al.
Published: (2023-07-01)

P1410: EFFICACY OBSERVATION OF A SECOND INFUSION OF BCMA-CAR-T CELLS IN PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA
by: Yi Wang, et al.
Published: (2023-08-01)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
by: Hujun Li, et al.
Published: (2022-10-01)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
by: Haobin Deng, et al.
Published: (2021-08-01)

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
by: Wei Li, et al.
Published: (2023-05-01)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
by: Yan Zhang, et al.
Published: (2022-09-01)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
by: James F. Wu, et al.
Published: (2023-07-01)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
by: Chunrui Li, et al.
Published: (2021-03-01)

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
by: Ming Shi, et al.
Published: (2024-04-01)

P970: SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
by: Y. Wang, et al.
Published: (2022-06-01)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
by: David M. Foureau, et al.
Published: (2020-07-01)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
by: Chetan Rathi, et al.
Published: (2021-08-01)

P944: A PHASE I STUDY OF C-CAR088, A NOVEL HUMANIZED ANTI-BCMA CAR T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: X. Qu, et al.
Published: (2022-06-01)

P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
by: Hila Magen, et al.
Published: (2023-08-01)

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma
by: Di Wang, et al.
Published: (2023-11-01)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
by: Lina Zhang, et al.
Published: (2021-01-01)

B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
by: Hanley N. Abramson
Published: (2020-07-01)

Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
by: Xiangmin Wang, et al.
Published: (2021-12-01)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
by: Ross Firestone, et al.
Published: (2023-08-01)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
by: Jarrod Longcor, et al.
Published: (2022-09-01)

Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis
by: Han Xu, et al.
Published: (2024-04-01)

S187: UPDATED PHASE 1/2 DATA OF SAFETY AND EFFICACY OF CT103A, FULLY HUMAN BCMA-DIRECTED CAR T CELLS, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: C. Li, et al.
Published: (2022-06-01)

P887: PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
by: Luis-Esteban Tamariz-Amador, et al.
Published: (2023-08-01)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
by: Quan Ren, et al.
Published: (2023-11-01)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
by: Christopher T. Su, et al.
Published: (2021-07-01)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
by: Martin Vogel, et al.
Published: (2023-05-01)

S103: EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR-T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: C. Fernandez De Larrea, et al.
Published: (2022-06-01)

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma
by: Deming Duan, et al.
Published: (2021-03-01)

P862: SERUM MASS SPECTROMETRY TO ANALYZE DISEASE RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR T-CELL THERAPY
by: I. Ortiz De Landazuri, et al.
Published: (2022-06-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
by: Borja Puertas, et al.
Published: (2022-03-01)

P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: D.E. Lowther, et al.
Published: (2023-05-01)